ReviewDrugs & aging2017
Recent Progress in the Pharmacotherapy of Alzheimer's Disease.
Review in Drugs & aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Targeting cholinergic dysfunction in Alzheimer's disease: Development of next-generation galantamine derivatives.Journal, genetic engineering & biotechnology · 2025Article
- Teucrium Polium ameliorates amyloid β-induced brain network disorders in rats: electrophysiological and behavioral studies.BMC complementary medicine and therapies · 2025Article
- Biological determinants of blood-based biomarker levels in Alzheimer's disease: role of nutrition, inflammation, and metabolic factors.Frontiers in aging neuroscience · 2025Review
- Plasma Proteomic Biomarkers in Alzheimer's Disease and Cardiovascular Disease: A Longitudinal Study.International journal of molecular sciences · 2024Article
- Galantamine Based Novel Acetylcholinesterase Enzyme Inhibitors: A Molecular Modeling Design Approach.Molecules (Basel, Switzerland) · 2023Article
- Osthole/borneol thermosensitive gel via intranasal administration enhances intracerebral bioavailability to improve cognitive impairment in APP/PS1 transgenic mice.Frontiers in pharmacology · 2023Article
- Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.European journal of clinical pharmacology · 2022Review
- News about Therapies of Alzheimer's Disease: Extracellular Vesicles from Stem Cells Exhibit Advantages Compared to Other Treatments.Biomedicines · 2022Review
- Pharmacological Management of Dysphagia in Patients with Alzheimer's Disease: A Narrative Review.Current Alzheimer research · 2022Article
- The Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Extracellular vesicles (exosomes and ectosomes) play key roles in the pathology of brain diseases.Molecular biomedicine · 2021Review
- Review
- K284-6111 alleviates memory impairment and neuroinflammation in Tg2576 mice by inhibition of Chitinase-3-like 1 regulating ERK-dependent PTX3 pathway.Journal of neuroinflammation · 2020Article
- Article
- Research Progress on Alzheimer's Disease and Resveratrol.Neurochemical research · 2020Review
- Circumdatin D Exerts Neuroprotective Effects by Attenuating LPS-Induced Pro-Inflammatory Responses and Downregulating Acetylcholinesterase ActivityFrontiers in pharmacology · 2020Article
- Potential therapeutic roles of retinoids for prevention of neuroinflammation and neurodegeneration in Alzheimer's disease.Neural regeneration research · 2019Review
- Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias.Drugs & aging · 2019Review
- The Role of NMDA Receptors in Alzheimer's Disease.Frontiers in neuroscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease is the most common major neurocognitive disorder with substantial social and economic impacts. This article is an update on current pharmacotherapy, advancements in biomarker use, and drugs in the pipeline for this disease. To date, no new drug has qualified to be added to the current therapeutic arsenal comprising cholinesterase inhibitors and the NMDA receptor antagonist memantine. Drugs in the pipeline include symptomatic therapies that are neurotransmitter-based, but mostly disease-modifying therapies. The latter have yielded disappointing results by focusing mainly on the two pathophysiological hallmarks of Alzheimer's disease: Aβ amyloid deposits and tau protein aggregates forming neurofibrillary tangles. These unsuccessful trials may have resulted from studying these drugs 'too late' relative to Alzheimer's disease onset, in addition to focusing only on the amyloid cascade. In fact, Alzheimer's disease is a complex multifactorial disease. Combining different biomarkers might enhance our ability to identify those patients most at risk of developing the disease, and better predict their conversion rates. Furthermore, adopting an integrative treatment approach by targeting additional pathophysiological pathways in Alzheimer's disease such as inflammation and oxidative stress could be the key to better outcomes in Alzheimer's disease pharmacotherapy research.
Indexed as
Identifiers
29116600What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.